Skip to content
You can now search across every topic, entity and event.What's new
Curenetics
OrganisationGB

Curenetics

UK biotech-quantum startup applying quantum algorithms and AI to cancer vaccine target identification.

Last refreshed: 22 April 2026 · Appears in 1 active topic

Key Question

Can quantum neoantigen discovery give Curenetics a licensing deal before clinical trials are even necessary?

Timeline for Curenetics

#214 Apr

Received DTC Quantum grant for quantum-AI cancer vaccine target research

UK Startups and Innovation: DTC Quantum names four Harwell cohort firms
View full timeline →
Follow UK Startups and Innovation →
Common Questions
What is Curenetics and what does it do?
Curenetics is a UK biotech-quantum startup applying quantum-adjacent algorithms and AI to identify cancer vaccine targets (neoantigen discovery). It was named in the April 2026 DTC Quantum cohort at Harwell.Source: Lowdown / UKRI STFC
How does quantum computing help with cancer vaccine research?
Identifying neoantigens — mutant protein fragments that can be targeted by personalised cancer vaccines — is a combinatorially hard optimisation problem that quantum algorithms can tackle more efficiently than classical computing at scale.
What funding did Curenetics receive from the DTC Quantum programme?
Curenetics received £50,000 to £100,000 in R&D funding, 50 hours of business support, and investor introductions as part of the April 2026 DTC Quantum cohort at Harwell.Source: UKRI STFC / NQCC

Background

Curenetics was named on 16 April 2026 in the inaugural DeepTech Catalyst Quantum (DTC Quantum) cohort at Harwell, delivered by UKRI STFC and the National Quantum Computing Centre (NQCC). Each cohort member receives £50,000 to £100,000 in R&D funding, 50 hours of business support, and investor introductions under the UK's £2bn ProQure quantum programme.

Curenetics is a UK biotech-quantum crossover startup that applies quantum-adjacent algorithms and classical AI to the identification of cancer vaccine targets — specifically to neoantigen discovery, the process of identifying the mutant protein fragments on a tumour cell that the immune system can be trained to attack. Neoantigen selection is a combinatorially hard problem well suited to quantum-inspired optimisation; Curenetics' approach positions it alongside established mRNA cancer-vaccine pipelines developed by BioNTech and Moderna, both of which are advancing personalised cancer vaccines through Phase II and Phase III trials.

Curenetics represents the healthcare vertical within DTC Quantum and is the cohort's highest-stakes commercial proposition: cancer vaccine development operates on long regulatory timelines, but a validated neoantigen-selection platform could be licensed to major biopharmaceutical firms independent of a full drug programme. Whether the DTC Quantum grant accelerates a licensing deal or private investment within 18 months is the benchmark the programme has set for itself.

More questions
What is neoantigen discovery in personalised cancer treatment?
Neoantigen discovery identifies tumour-specific mutant protein fragments that distinguish cancer cells from healthy ones. These neoantigens are used to design personalised cancer vaccines that train the immune system to attack the tumour.
Which companies are developing personalised cancer vaccines?
BioNTech and Moderna are the furthest advanced, with personalised mRNA cancer vaccines in Phase II and III trials. Curenetics aims to improve neoantigen target selection using quantum-aided computation.